ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 01 Jul 2022
Last Updated on 01 Jul 2022

A- A+

Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended: sitagliptin 25 mg, 50 mg and 100 mg tablets in line with their registered indications for improving glycemic control in patients with type 2 diabetes mellitus, in view of acceptable price proposal from the manufacturer.
Subsidy status
Sitagliptin 25 mg, 50 mg and 100 mg tablets are recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications. SDL subsidy does not apply to combination products containing sitagliptin or other DPP-4 inhibitors.

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

sitagliptin 25 mg, 50 mg and 100 mg tablets

in line with their registered indications for improving glycemic control in patients with type 2 diabetes mellitus, in view of acceptable price proposal from the manufacturer.

Subsidy status

Sitagliptin 25 mg, 50 mg and 100 mg tablets are recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications.

SDL subsidy does not apply to combination products containing sitagliptin or other DPP-4 inhibitors.

Sitagliptin for treating type 2 diabetes mellitus (1 Jul 22)